Abstract
Inositol hexaphosphate (IP6, InsP6) is a polyphosphorylated carbohydrate with diverse signaling properties. IP6 is plentiful in organisms as diverse as yeast, actinobacteria, mammals and plants. In the plant kingdom, IP6 accumulates during seed development; during germination it is broken down into lower inositol phosphates and micronutrients to maintain seedling. IP6 is the most abundant of the intracellular inositol phosphates in eukaryotes. In mammals IP6 maintains homeostasis, stores phosphate and acts as a strong anti-oxidant and neurotransmitter. IP6’s rapid phosphate turnover properties justify its critical role in cellular pathways involved in signal transduction, control of cell proliferation and differentiation, RNA export, DNA repair, energy transduction and ATP regeneration. The health benefits of IP6 have been demonstrated to lower serum cholesterol level, normalize pathological platelet activity and prevent pathological calcification and kidney stone formation. It is also a potent antioxidant and immunity enhancer. However, it is the field of cancer prevention and therapy that may be the biggest career for IP6. In this review we present updated knowledge on signaling events caused by this fascinating, ubiquitous molecule that has numerous functions.
Keywords: IP6, inositol, phytate, polyphosphates, signal transduction, nutraceuticals, actinobacteria, myo-isoform, pentakisphosphate, Myxobacteria
Current Signal Transduction Therapy
Title:IP6 (Inositol Hexaphosphate) as a Signaling Molecule
Volume: 7 Issue: 3
Author(s): Abul Kalam Shamsuddin and Sanchita Bose
Affiliation:
Keywords: IP6, inositol, phytate, polyphosphates, signal transduction, nutraceuticals, actinobacteria, myo-isoform, pentakisphosphate, Myxobacteria
Abstract: Inositol hexaphosphate (IP6, InsP6) is a polyphosphorylated carbohydrate with diverse signaling properties. IP6 is plentiful in organisms as diverse as yeast, actinobacteria, mammals and plants. In the plant kingdom, IP6 accumulates during seed development; during germination it is broken down into lower inositol phosphates and micronutrients to maintain seedling. IP6 is the most abundant of the intracellular inositol phosphates in eukaryotes. In mammals IP6 maintains homeostasis, stores phosphate and acts as a strong anti-oxidant and neurotransmitter. IP6’s rapid phosphate turnover properties justify its critical role in cellular pathways involved in signal transduction, control of cell proliferation and differentiation, RNA export, DNA repair, energy transduction and ATP regeneration. The health benefits of IP6 have been demonstrated to lower serum cholesterol level, normalize pathological platelet activity and prevent pathological calcification and kidney stone formation. It is also a potent antioxidant and immunity enhancer. However, it is the field of cancer prevention and therapy that may be the biggest career for IP6. In this review we present updated knowledge on signaling events caused by this fascinating, ubiquitous molecule that has numerous functions.
Export Options
About this article
Cite this article as:
Kalam Shamsuddin Abul and Bose Sanchita, IP6 (Inositol Hexaphosphate) as a Signaling Molecule, Current Signal Transduction Therapy 2012; 7 (3) . https://dx.doi.org/10.2174/157436212802481628
DOI https://dx.doi.org/10.2174/157436212802481628 |
Print ISSN 1574-3624 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-389X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
HspB5/αB-Crystallin: Properties and Current Progress in Neuropathy
Current Neurovascular Research Modulation of Cardiovascular Function by Adipokines
Cardiovascular & Hematological Disorders-Drug Targets Cutting through the Complexities of mTOR for the Treatment of Stroke
Current Neurovascular Research Peripartum Cardiomyopathy: An Intensivist's Perspective
Current Women`s Health Reviews Recombinant Tissue-Type Plasminogen Activator (Alteplase) in the Management of Acute Ischemic Stroke: A Review of its Pharmacological Properties, Efficacy, Safety and Pharmacoeconomic Aspects
Current Drug Therapy Partial A1 Adenosine Receptor Agonists from a Molecular Perspective and Their Potential Use as Chronic Ventricular Rate Control Agents During Atrial Fibrillation (AF)
Current Topics in Medicinal Chemistry Mitochondria-targeted Resveratrol Derivatives Act as Cytotoxic Pro-oxidants
Current Pharmaceutical Design A Promising Future for Peptides in Ophthalmology: Work Effectively and Smartly
Current Medicinal Chemistry Platelet GPIIb/IIIa Receptor Antagonists in Human Ischemic Brain Disease
Current Vascular Pharmacology Oxidative Stress and Antioxidative Enzyme Activities in Chronic Kidney Disease and Different Types of Renal Replacement Therapy
Current Protein & Peptide Science Biological and Pharmacological Activities of Carvacrol and Carvacrol Bearing Essential Oils
Current Pharmaceutical Design Disruption of Circadian Rhythms and Sleep in Critical Illness and its Impact on Innate Immunity
Current Pharmaceutical Design Neuroprotection by NMDA Receptor Antagonists in a Variety of Neuropathologies
Current Drug Targets Employing New Cellular Therapeutic Targets for Alzheimers Disease: A Change for the Better?
Current Neurovascular Research Iptakalim Hydrochloride and Neuronal Protection
Current Neuropharmacology Proline-Rich Peptides: Multifunctional Bioactive Molecules as New Potential Therapeutic Drugs
Current Protein & Peptide Science Innate Immune Inflammatory Response in the Acutely Ischemic Myocardium
Medicinal Chemistry The Putative Use of Lithium in Alzheimer’s Disease
Current Alzheimer Research The Circadian PER2 Enhancer Nobiletin Reverses the Deleterious Effects of Midazolam in Myocardial Ischemia and Reperfusion Injury
Current Pharmaceutical Design Recent Trials for FTY720 (Fingolimod): A New Generation of Immunomodulators Structurally Similar to Sphingosine
Reviews on Recent Clinical Trials